MagAssist, founded in 2017, is led by Dr. Po-Lin Hsu, distinguished professor at Soochow University and expert of the National Major Talent Project Youth Group, together with domestic and overseas teams that have been engaged in development of artificial hearts for decades. Using core platform technologies such as mechatronics, magnetic levitation, and computational fluid dynamics. MagAssist are one of only two companies in the world who have successfully built extracorporeal artificial heart products with magnetic levitation, and the first in China. In the future, platform solutions for extracorporeal life support systems for different populations, assistance needs, and clinical usage scenarios will be developed for cardiovascular patients in China and worldwide.
Short-to-medium-term extracorporeal ventricular assist devices (artificial hearts) can be used to provide treatment for acute heart failure and transitional treatments for patients with end-stage heart failure. They can also be widely applied to treat critically ill patients whilst recovering from cardiac surgery. Thousands of patients in China die every year from fulminant myocarditis, acute heart failure, and cardiac arrest caused by trauma such as H1N1, severe injury, drowning, gas poisoning, myocardial infarction, and unexplained cardiac arrest following thoracotomy. The extracorporeal artificial heart is a life-saving first aid and treatment method for these patients, and can improve their survival rate by 50%.